Laboratory Medicine ›› 2024, Vol. 39 ›› Issue (12): 1181-1189.DOI: 10.3969/j.issn.1673-8640.2024.12.009
Previous Articles Next Articles
ZOU Chen1, XU Runhao2, DING Yi3, ZHANG Jie2, WENG Wenhao1, WANG Zhenhua4, CAO Yun2()
Received:
2024-05-06
Revised:
2024-08-27
Online:
2024-12-30
Published:
2025-01-06
CLC Number:
ZOU Chen, XU Runhao, DING Yi, ZHANG Jie, WENG Wenhao, WANG Zhenhua, CAO Yun. Colorectal cancer screening model based on ProteomeXchange database[J]. Laboratory Medicine, 2024, 39(12): 1181-1189.
Add to citation manager EndNote|Ris|BibTeX
URL: https://www.shjyyx.com/EN/10.3969/j.issn.1673-8640.2024.12.009
蛋白ID | 蛋白基因符号 | 蛋白名称 | 生物学进程① | 细胞成分② | 分子功能③ | KEGG通路④ | 连接节点⑤ | 差异倍数 | 候选蛋白 |
---|---|---|---|---|---|---|---|---|---|
P02647 | APOA1 | APOA1 | 0 | 8 | 0 | 2 | 20 | 0.72 | apo A1 |
P02656 | APOC3 | APOC3 | 0 | 3 | 0 | 2 | 29 | 1.37 | apo C3 |
P00450 | CP | CER | 0 | 2 | 0 | 0 | 23 | 1.45 | CER |
P02741 | CRP | CRP | 2 | 0 | 1 | 0 | 16 | 2.59 | CRP |
P0C0L4 | C4A | C4A | 5 | 2 | 0 | 5 | 19 | 1.90 | C4 |
P02671 | FGA | FGA | 7 | 10 | 2 | 3 | 38 | 2.19 | Fib |
P02751 | FN1 | FN | 0 | 10 | 3 | 0 | 29 | 0.02 | FN |
P00390 | GSR | GR | 1 | 3 | 0 | 0 | 22 | 0.30 | GR |
P02787 | TF | TRF | 1 | 5 | 0 | 0 | 17 | 0.57 | TRF |
P61769 | B2M | β2-MG | 1 | 4 | 1 | 0 | 24 | 1.59 | β2-MG |
蛋白ID | 蛋白基因符号 | 蛋白名称 | 生物学进程① | 细胞成分② | 分子功能③ | KEGG通路④ | 连接节点⑤ | 差异倍数 | 候选蛋白 |
---|---|---|---|---|---|---|---|---|---|
P02647 | APOA1 | APOA1 | 0 | 8 | 0 | 2 | 20 | 0.72 | apo A1 |
P02656 | APOC3 | APOC3 | 0 | 3 | 0 | 2 | 29 | 1.37 | apo C3 |
P00450 | CP | CER | 0 | 2 | 0 | 0 | 23 | 1.45 | CER |
P02741 | CRP | CRP | 2 | 0 | 1 | 0 | 16 | 2.59 | CRP |
P0C0L4 | C4A | C4A | 5 | 2 | 0 | 5 | 19 | 1.90 | C4 |
P02671 | FGA | FGA | 7 | 10 | 2 | 3 | 38 | 2.19 | Fib |
P02751 | FN1 | FN | 0 | 10 | 3 | 0 | 29 | 0.02 | FN |
P00390 | GSR | GR | 1 | 3 | 0 | 0 | 22 | 0.30 | GR |
P02787 | TF | TRF | 1 | 5 | 0 | 0 | 17 | 0.57 | TRF |
P61769 | B2M | β2-MG | 1 | 4 | 1 | 0 | 24 | 1.59 | β2-MG |
组别 | 例数 | apo A1/(g·L-1) | apo C3/(mg·L-1) | CER/(g·L-1) | CRP/(mg·L-1) | C4/(g·L-1) | ||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|
CRC组 | 108 | 1.15±0.26 | 79.5(68.9~96.4) | 0.27(0.24~0.32) | 10.75(2.86~48.05) | 0.26(0.21~0.32) | ||||||
正常对照组 | 100 | 1.61±0.27 | 104.1(87.7~129.3) | 0.24(0.22~0.27) | 2.86(2.86~2.86) | 0.22(0.18~0.27) | ||||||
统计值 | 12.488 | -6.531 | -4.509 | -8.586 | -4.059 | |||||||
P值 | <0.001 | <0.001 | <0.001 | <0.001 | <0.001 | |||||||
组别 | FN/(mg·L-1) | Fib/(g·L-1) | GR/(U·L-1) | TRF/(g·L-1) | β2-MG/(mg·L-1) | |||||||
CRC组 | 284.05(215.50~331.10) | 3.21(2.57~4.06) | 46.26±10.17 | 2.12±0.53 | 2.05(1.67~2.58) | |||||||
正常对照组 | 349.50(304.93~409.48) | 2.74(2.36~3.22) | 52.99±7.51 | 2.56±0.37 | 1.57(1.34~1.81) | |||||||
统计值 | -5.828 | -4.042 | 5.386 | 6.808 | -6.940 | |||||||
P值 | <0.001 | <0.001 | <0.001 | <0.001 | <0.001 | |||||||
组别 | CEA/(ng·mL-1) | CA19-9/(U·mL-1) | CA242/(U·mL-1) | CA50/(U·mL-1) | CA72-4/(U·mL-1) | |||||||
CRC组 | 3.46(1.81~8.48) | 11.20(5.95~17.80) | 5.17(2.89~11.89) | 6.48(3.94~11.22) | 1.75(1.50~3.87) | |||||||
正常对照组 | 1.58(1.01~2.25) | 8.14(5.80~11.68) | 5.18(3.52~7.34) | 5.46(3.15~9.03) | 1.63(1.50~2.99) | |||||||
统计值 | -6.716 | -2.848 | -0.730 | -1.788 | -1.207 | |||||||
P值 | <0.001 | 0.004 | 0.466 | 0.074 | 0.228 |
组别 | 例数 | apo A1/(g·L-1) | apo C3/(mg·L-1) | CER/(g·L-1) | CRP/(mg·L-1) | C4/(g·L-1) | ||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|
CRC组 | 108 | 1.15±0.26 | 79.5(68.9~96.4) | 0.27(0.24~0.32) | 10.75(2.86~48.05) | 0.26(0.21~0.32) | ||||||
正常对照组 | 100 | 1.61±0.27 | 104.1(87.7~129.3) | 0.24(0.22~0.27) | 2.86(2.86~2.86) | 0.22(0.18~0.27) | ||||||
统计值 | 12.488 | -6.531 | -4.509 | -8.586 | -4.059 | |||||||
P值 | <0.001 | <0.001 | <0.001 | <0.001 | <0.001 | |||||||
组别 | FN/(mg·L-1) | Fib/(g·L-1) | GR/(U·L-1) | TRF/(g·L-1) | β2-MG/(mg·L-1) | |||||||
CRC组 | 284.05(215.50~331.10) | 3.21(2.57~4.06) | 46.26±10.17 | 2.12±0.53 | 2.05(1.67~2.58) | |||||||
正常对照组 | 349.50(304.93~409.48) | 2.74(2.36~3.22) | 52.99±7.51 | 2.56±0.37 | 1.57(1.34~1.81) | |||||||
统计值 | -5.828 | -4.042 | 5.386 | 6.808 | -6.940 | |||||||
P值 | <0.001 | <0.001 | <0.001 | <0.001 | <0.001 | |||||||
组别 | CEA/(ng·mL-1) | CA19-9/(U·mL-1) | CA242/(U·mL-1) | CA50/(U·mL-1) | CA72-4/(U·mL-1) | |||||||
CRC组 | 3.46(1.81~8.48) | 11.20(5.95~17.80) | 5.17(2.89~11.89) | 6.48(3.94~11.22) | 1.75(1.50~3.87) | |||||||
正常对照组 | 1.58(1.01~2.25) | 8.14(5.80~11.68) | 5.18(3.52~7.34) | 5.46(3.15~9.03) | 1.63(1.50~2.99) | |||||||
统计值 | -6.716 | -2.848 | -0.730 | -1.788 | -1.207 | |||||||
P值 | <0.001 | 0.004 | 0.466 | 0.074 | 0.228 |
项目 | AUC(95%CI①) | 最佳临界值 | 敏感性/% | 特异性/% | 约登指数 |
---|---|---|---|---|---|
apo A1 | 0.898(0.849~0.936) | 1.32 g·L-1 | 81.48 | 86.00 | 0.67 |
apo C3 | 0.762(0.698~0.818) | 82.9 mg·L-1 | 56.48 | 85.00 | 0.41 |
CER | 0.681(0.613~0.743) | 0.25 g·L-1 | 63.89 | 66.00 | 0.30 |
CRP | 0.803(0.742~0.854) | 3.26 mg·L-1 | 65.74 | 92.00 | 0.58 |
C4 | 0.663(0.594~0.727) | 0.23 g·L-1 | 66.67 | 58.00 | 0.25 |
Fib | 0.662(0.589~0.736) | 3.54 g·L-1 | 37.96 | 92.00 | 0.30 |
FN | 0.734(0.669~0.793) | 290.10 mg·L-1 | 55.56 | 83.00 | 0.39 |
GR | 0.749(0.684~0.806) | 45.80 U·L-1 | 57.41 | 85.00 | 0.42 |
TRF | 0.752(0.687~0.809) | 2.12 g·L-1 | 54.63 | 92.00 | 0.47 |
β2-MG | 0.779(0.716~0.833) | 2.00 mg·L-1 | 55.56 | 90.00 | 0.46 |
CEA | 0.770(0.707~0.825) | 2.52 ng·mL-1 | 62.96 | 82.00 | 0.45 |
CA19-9 | 0.614(0.545~0.681) | 11.90 U·mL-1 | 48.15 | 77.00 | 0.25 |
项目 | AUC(95%CI①) | 最佳临界值 | 敏感性/% | 特异性/% | 约登指数 |
---|---|---|---|---|---|
apo A1 | 0.898(0.849~0.936) | 1.32 g·L-1 | 81.48 | 86.00 | 0.67 |
apo C3 | 0.762(0.698~0.818) | 82.9 mg·L-1 | 56.48 | 85.00 | 0.41 |
CER | 0.681(0.613~0.743) | 0.25 g·L-1 | 63.89 | 66.00 | 0.30 |
CRP | 0.803(0.742~0.854) | 3.26 mg·L-1 | 65.74 | 92.00 | 0.58 |
C4 | 0.663(0.594~0.727) | 0.23 g·L-1 | 66.67 | 58.00 | 0.25 |
Fib | 0.662(0.589~0.736) | 3.54 g·L-1 | 37.96 | 92.00 | 0.30 |
FN | 0.734(0.669~0.793) | 290.10 mg·L-1 | 55.56 | 83.00 | 0.39 |
GR | 0.749(0.684~0.806) | 45.80 U·L-1 | 57.41 | 85.00 | 0.42 |
TRF | 0.752(0.687~0.809) | 2.12 g·L-1 | 54.63 | 92.00 | 0.47 |
β2-MG | 0.779(0.716~0.833) | 2.00 mg·L-1 | 55.56 | 90.00 | 0.46 |
CEA | 0.770(0.707~0.825) | 2.52 ng·mL-1 | 62.96 | 82.00 | 0.45 |
CA19-9 | 0.614(0.545~0.681) | 11.90 U·mL-1 | 48.15 | 77.00 | 0.25 |
模型(步数) | 纳入模型的生物标志物 | 移除项① | AUC | 敏感性/% | 特异性/% | P值② |
---|---|---|---|---|---|---|
1 | apo A1、CRP、FN、GR、TRF、β2-MG、CEA | 0.963 | 87.21 | 93.75 | ||
2 | apo A1、CRP、FN、GR、TRF、CEA | β2-MG | 0.963 | 87.21 | 93.75 | 0.935 |
3③ | apo A1、CRP、FN、TRF、CEA | GR | 0.959 | 87.21 | 92.50 | 0.145 |
4 | apo A1、CRP、FN、CEA | TRF | 0.955 | 86.05 | 90.00 | 0.048 |
模型(步数) | 纳入模型的生物标志物 | 移除项① | AUC | 敏感性/% | 特异性/% | P值② |
---|---|---|---|---|---|---|
1 | apo A1、CRP、FN、GR、TRF、β2-MG、CEA | 0.963 | 87.21 | 93.75 | ||
2 | apo A1、CRP、FN、GR、TRF、CEA | β2-MG | 0.963 | 87.21 | 93.75 | 0.935 |
3③ | apo A1、CRP、FN、TRF、CEA | GR | 0.959 | 87.21 | 92.50 | 0.145 |
4 | apo A1、CRP、FN、CEA | TRF | 0.955 | 86.05 | 90.00 | 0.048 |
[1] | SUNG H, FERLAY J, SIEGEL R L, et al. Global cancer statistics 2020:GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J]. CA Cancer J Clin, 2021, 71(3):209-249. |
[2] | WOLF A M D, FONTHAM E T H, CHURCH T R, et al. Colorectal cancer screening for average-risk adults:2018 guideline update from the American Cancer Society[J]. CA Cancer J Clin, 2018, 68(4):250-281. |
[3] |
BRENNER H, KLOOR M, POX C P. Colorectal cancer[J]. Lancet, 2014, 383(9927):1490-1502.
DOI PMID |
[4] | FANG Z, HE M, SONG M. Serum lipid profiles and risk of colorectal cancer:a prospective cohort study in the UK Biobank[J]. Br J Cancer, 2021, 124(3):663-670. |
[5] | LEE P Y, CHIN S F, LOW T Y, et al. Probing the colorectal cancer proteome for biomarkers:current status and perspectives[J]. J Proteomics, 2018,187:93-105. |
[6] | HELSINGEN L M, VANDVIK P O, JODAL H C, et al. Colorectal cancer screening with faecal immunochemical testing,sigmoidoscopy or colonoscopy:a clinical practice guideline[J]. BMJ, 2019,367:l5515. |
[7] | REUMKENS A, RONDAGH E J, BAKKER C M, et al. Post-colonoscopy complications:a systematic review,time trends,and meta-analysis of population-based studies[J]. Am J Gastroenterol, 2016, 111(8):1092-1101. |
[8] | SHAUKAT A, KAHI C J, BURKE C A, et al. ACG clinical guidelines:colorectal cancer screening 2021[J]. Am J Gastroenterol, 2021, 116(3):458-479. |
[9] | 房静远, 李延青, 陈萦晅, 等. 中国结直肠肿瘤综合预防共识意见(2021年,上海)[J]. 胃肠病学, 2021, 26(5):279-311. |
[10] | BENAMOUZIG R, BARRÉ S, SAURIN J C, et al. Cost-effectiveness analysis of alternative colorectal cancer screening strategies in high-risk individuals[J]. Therap Adv Gastroenterol, 2021,14:17562848211002359. |
[11] | IMPERIALE T F, RANSOHOFF D F, ITZKOWITZ S H, et al. Multitarget stool DNA testing for colorectal-cancer screening[J]. N Engl J Med, 2014, 370(14):1287-1297. |
[12] |
上海市抗癌协会大肠癌专业委员会. 结直肠癌早筛、早诊、早治上海方案(2023年版)[J]. 中国癌症杂志, 2024, 34(1):13-66.
DOI |
[13] | URBIOLA-SALVADOR V, JABOSKA A, MIROSZEWSKA D, et al. Plasma protein changes reflect colorectal cancer development and associated inflammation[J]. Front Oncol, 2023,13:1158261. |
[14] | NICOLINI A, FERRARI P, DUFFY M J, et al. Intensive risk-adjusted follow-up with the CEA,TPA,CA19.9,and CA72.4 tumor marker panel and abdominal ultrasonography to diagnose operable colorectal cancer recurrences:effect on survival[J]. Arch Surg, 2010, 145(12):1177-1183. |
[15] | BHARDWAJ M, GIES A, WERNER S, et al. Blood-based protein signatures for early detection of colorectal cancer:a systematic review[J]. Clin Transl Gastroenterol, 2017, 8(11):e128. |
[16] | HORNBROOK M C, GOSHEN R, CHOMAN E, et al. Early colorectal cancer detected by machine learning model using gender,age,and complete blood count data[J]. Dig Dis Sci, 2017, 62(10):2719-2727. |
[17] | ZHANG Z. An in vitro diagnostic multivariate index assay(IVDMIA)for ovarian cancer:harvesting the power of multiple biomarkers[J]. Rev Obstet Gynecol, 2012, 5(1):35-41. |
[18] | ZHOU H, WANG X C, YUAN B B, et al. Clinical value of combining serum tumor marker detection with fecal occult blood testing in diagnosing colorectal cancer[J]. J Physiol Pharmacol, 2022, 73(3):443-449. |
[19] | PANKAJ J, KUMARI J R, KIM W, et al. Insulin-like growth factor-1,IGF-binding protein-3,C-peptide and colorectal cancer:a case-control study[J]. Asian Pac J Cancer Prev, 2015, 16(9):3735-3740. |
[20] | VORONOVA V, GLYBOCHKO P, SVISTUNOV A, et al. Diagnostic value of combinatorial markers in colorectal carcinoma[J]. Front Oncol, 2020,10:832. |
[21] |
KWON Y, PARK S J, NGUYEN B T, et al. Multi-layered proteogenomic analysis unravels cancer metastasis directed by MMP-2 and focal adhesion kinase signaling[J]. Sci Rep, 2021, 11(1):17130.
DOI PMID |
[22] | MARTÍN-GARCÍA D, GARCÍA-ARANDA M, REDONDO M. Biomarker identification through proteomics in colorectal cancer[J]. Int J Mol Sci, 2024, 25(4):2283. |
[23] |
SHI Y, LIU Z. Serum miR-92a-1 is a novel diagnostic biomarker for colorectal cancer[J]. J Cell Mol Med, 2020, 24(15):8363-8367.
DOI PMID |
[24] | SANTOS M D, BARROS I, BRANDÃO P, et al. Amino acid profiles in the biological fluids and tumor tissue of CRC patients[J]. Cancers(Basel), 2023, 16(1):69. |
[25] |
兰俊, 路舒婷, 杨健睿. 结直肠癌患者血清IL-26、IL-27水平检测的临床意义[J]. 检验医学, 2024, 39(1):7-12.
DOI |
[1] | ZHENG Hui, CHEN Yingxiu, YE Lüyin, LU Renquan, GUO Lin. Relationship between peripheral blood T lymphocyte subsets and tumor progression in patients with colorectal cancer [J]. Laboratory Medicine, 2024, 39(4): 330-335. |
[2] | XU Yunchuan, HUANGFU Yuchan, MA Yanhui. Effect of highly expressed IL-35 on Th1 and Th17 plasticity in colorectal cancer [J]. Laboratory Medicine, 2024, 39(4): 343-350. |
[3] | LAN Jun, LU Shuting, YANG Jianrui. Roles of serum IL-26 and IL-27 levels in patients with colorectal cancer [J]. Laboratory Medicine, 2024, 39(1): 7-12. |
[4] | SUN Chuanyu, ZHAO Xiaojun, GE Shengyang, ZHANG Yang. Transcription factors in prostate cancer progression [J]. Laboratory Medicine, 2023, 38(9): 818-824. |
[5] | LI Liangshan, ZHAO Hu, WANG Shiwen. Screening potential prognostic biomarkers of colorectal cancer based on weighted gene co-expression network analysis [J]. Laboratory Medicine, 2023, 38(9): 825-832. |
[6] | SUN Zepeng, WANG Hongbin, WANG Jiandong, SONG Dewei, XIAO Peng. Analysis and progress of peptide and protein biomarker methodology for myocardial injury [J]. Laboratory Medicine, 2023, 38(8): 784-789. |
[7] | ZHU Rixiang, YIN Jie. Relationship between soluble growth stimulating gene 2 protein and clinicopathological features and prognosis in patients with colorectal cancer [J]. Laboratory Medicine, 2023, 38(7): 629-633. |
[8] | ZHANG Min, WANG Binyu, CHI Weiqun, LIU Yu. Research progress of exosomal non-coding RNA as biomarkers for disease diagnosis [J]. Laboratory Medicine, 2023, 38(6): 594-598. |
[9] | GAO Feng. Clinical application of novel tumor biomarkers:prospects and challenges [J]. Laboratory Medicine, 2023, 38(4): 303-306. |
[10] | JIANG Mengying, LIU Yiwen, HE Yiqing, XU Jing, YANG Cuixia, GAO Feng, DU Yan. Clinical role of serum S1P in the early diagnosis of colorectal cancer [J]. Laboratory Medicine, 2023, 38(4): 307-312. |
[11] | ZHANG Guoliang, LIU Yiwen, HE Yiqing, XU Jing, YANG Cuixia, GAO Feng, LIU Hua. Roles of serum HYAL1 and HA in the auxiliary diagnosis and therapeutic monitoring of colorectal cancer [J]. Laboratory Medicine, 2023, 38(4): 313-319. |
[12] | YANG Jielin, WANG Xiaoyuan, LI Haixia. Expression and interaction of TRX and TXNIP in colorectal cancer [J]. Laboratory Medicine, 2023, 38(4): 330-336. |
[13] | ZHOU Furong, LI Yanzhu, LIU Yonggan. Application of lncRNA SNP in colorectal cancer susceptibility prediction and prognosis assessment [J]. Laboratory Medicine, 2023, 38(12): 1206-1210. |
[14] | LU Qiyuan, LU Jianhua. Biomarker research progress for the diagnosis of periprosthetic joint infection [J]. Laboratory Medicine, 2023, 38(10): 997-1002. |
[15] | CHEN Xuewei, LI Yirong. Candidate biomarkers in metabolic syndrome based on GEO database [J]. Laboratory Medicine, 2023, 38(1): 32-38. |
Viewed | ||||||
Full text |
|
|||||
Abstract |
|
|||||